Last reviewed · How we verify
UIC201602 and co-administration of UIC201601 and UIC201602 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
UIC201602 and co-administration of UIC201601 and UIC201602 (UIC201602 and co-administration of UIC201601 and UIC201602) — Korea United Pharm. Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| UIC201602 and co-administration of UIC201601 and UIC201602 TARGET | UIC201602 and co-administration of UIC201601 and UIC201602 | Korea United Pharm. Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- UIC201602 and co-administration of UIC201601 and UIC201602 CI watch — RSS
- UIC201602 and co-administration of UIC201601 and UIC201602 CI watch — Atom
- UIC201602 and co-administration of UIC201601 and UIC201602 CI watch — JSON
- UIC201602 and co-administration of UIC201601 and UIC201602 alone — RSS
Cite this brief
Drug Landscape (2026). UIC201602 and co-administration of UIC201601 and UIC201602 — Competitive Intelligence Brief. https://druglandscape.com/ci/uic201602-and-co-administration-of-uic201601-and-uic201602. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab